Investor Presentaiton
Zydus at a Glance
>$2
Global Revenues¹
5th
bn
Largest generic Co. in US
in terms of prescription³
Over
Revenues from branded
50%
business (India, EM and
Wellness)
Among
Top 3
In 60% of product
families marketed in US³
00
1st
$4.5
bn
Market Capitalization²
12
Brands among Top
300 in India4
1st
36 Mfg. sites Producing
>28 bn pills annually
1.
123
2.
3.
Assuming exchange rate of Rs. 74.5 per USD
As on 19th May, 2022, exchange rate of Rs. 77.65 per USD
IQVIA, Regulatory Insights, MAT March 2022 TRX
23 K
Zydans globally incl.
1400 scientists (R&D)
22
4. As per AWACS MAT March 2022
zydus
Dedicated To Life
R&D Centers
For NCE, APIs, Gx formulations,
Biosimilars and Vaccines
Approved product for
NASH in India - (Bilypsa®-
Saroglitazar)
OSD formulation for anemia
associated with CKD -
OxemiaTM (Desidustat)
Biosimilars in portfolio
including 13 launched in
India
12View entire presentation